Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)

This study has been completed.
Sponsor:
Information provided by:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00153075
First received: September 9, 2005
Last updated: October 28, 2013
Last verified: October 2013

September 9, 2005
October 28, 2013
September 2005
December 2005   (final data collection date for primary outcome measure)
Whole lung deposition [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Primary Endpoint: The primary endpoint is whole lung deposition.
Complete list of historical versions of study NCT00153075 on ClinicalTrials.gov Archive Site
  • Central lung zone deposition [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Intermediate lung zone deposition [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
  • Peripheral lung zone deposition [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Ratio of peripheral to central zone deposition [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Oropharyngeal deposition [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Device deposition and exhaled air filter deposition [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • FEV1 15, 30 and 60 minutes post-administration (safety only) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Secondary Endpoint: The Respimat® inhaler will also be compared with the MDI in terms of o Central lung zone deposition o Intermediate lung zone deposition o Peripheral lung zone deposition o Ratio of peripheral to central zone deposition
Not Provided
Not Provided
 
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
A Randomised Open Label, Six Way, Cross-over Scintigraphic Evaluation of the Effect of Inspiratory Flow Rate on Lung and Oropharyngeal Deposition With the Respimat Inhaler vs. a Metered Dose Inhaler (HFA-MDI) Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD).

The objective of this trial is to compare the total and regional deposition of aerosol in the lungs and oropharynx of patients with COPD at 3 different inspiratory flow rates following inhalation of Berodual delivered via the Respimat inhaler and Berodual? delivered via an HFA-metered dose inhaler.

This is a single dose, randomised, active-controlled, six period, open-label cross-over trial in adult patients with COPD.

Berodual (fenoterol hydrobromide 50 g + ipratropium bromide 20 g) will be delivered via the Respimat inhaler and the MDI at 3 different inspiratory flow rates: 15 L/min, 30 L/min and 90 L/min. The optimal flow rate is expected to be 30 L/min for both inhalers.

On each test day patients will practise the inhalation manoeuvre with either a placebo Respimat or MDI inhaler. When patients can perform the inhalation technique correctly and they can obtain the required inspiratory flow rates the placebo will be replaced with the radio-labelled formulation.

The primary analysis will be carried out using the Sign Test. This is a non-parametric analysis in which no assumptions are made about the shape of the distribution of the responses from the Respimat inhaler and from the MDI under the null hypothesis.

Study Hypothesis:

The null hypothesis is that flow rate has the same effect on the Respimat and MDI inhalers. The alternative hypothesis is that flow rate has a different effect on the Respimat inhaler than on the MDI inhaler.

This means that under the null hypothesis the median of the differences between the Respimat inhaler and MDI pairs is zero i.e., the differences are equally lik ely to be positive or negative. Under the alternative hypothesis the median of the differences between the Respimat inhaler and MDI pairs is not zero i.e., the frequencies of the positive and negative signs are different.

Comparison(s):

For the primary comparison the whole lung deposition achieved for each patient at the 90 L/min flow rate will be expressed as a percentage of the whole lung deposition achieved by that patient at the 30 L/min flow rate for the Respimat and MDI inhalers separately. The difference between each pair of observations ((Respimat 90 L/min / Respimat 30 L/min) - (MDI 90 L/min / MDI 30 L/min)) will then be calculated and the sign of the direction of the difference noted i.e., positive or negative. The probability associated with the occurrence of the observed number of positive and negative differences will then be determined by reference to the binomial distribution with the probability of a positive or negative difference equal to 0.5 under the null hypothesis. If the alternative hypothesis is, however, true and flow rate does in fact have less effect on the Respimat inhaler than on the MDI inhaler, then there is likely to be a statistically significant greater number of positive differences.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Pulmonary Disease, Chronic Obstructive
  • Asthma
  • Device: Berodual Respimat
  • Device: Berodual HFA-MDI
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
19
December 2005
December 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • COPD patients:

    • FEV1 less or equal 65 % pre
    • FEV1 less or equal 70 % of FVC

Exclusion Criteria:

  • Patients with any upper respiratory infection in the past 14 days prior to the Screening Visit (Visit 1)
  • Patients with any unstable or life-threatening cardiac arrhythmia
Both
40 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00153075
215.1364
Not Provided
Not Provided
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Study Coordinator B.I. Pharma GmbH & Co. KG
Boehringer Ingelheim
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP